Erratum: Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia (Science Translational Medicine (2015) 7 (290ra88) DOI: 10.1126/scitranslmed.aaa5038);Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia

Science Translational Medicine

Volumn 7, Issue 290, 2015, Pages

  Holobotovskyy, Vasyl ^a   Chong, Yee Seng ^a   Burchell, Jennifer ^a   He, Bo ^a   Phillips, Michael ^a,b   Leader, Leo ^c   Murphy, Timothy V ^c   Sandow, Shaun L ^c,d   McKitrick, Douglas J ^a   Charles, Adrian K ^a,h   Tare, Marianne ^e   Arnolda, Leonard F ^f   Ganss, Ruth ^a,g  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF BALLARAT   (Australia)

^g AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^h SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RGS PROTEIN; RGS5 PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; RGS5 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FEMALE; LOW BIRTH WEIGHT; MATERNAL HYPERTENSION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLACENTA DISORDER; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; ADAPTATION; ANIMAL; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY;

ADAPTATION, PHYSIOLOGICAL; ANGIOTENSIN II; ANIMALS; FEMALE; MICE; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; RGS PROTEINS;

EID: 84930440373     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.abf2620     Document Type: Erratum

References (56)

1. C. E. Powe, R. J. Levine, S. A. Karumanchi, Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123, 2856-2869 (2011).
2. A. B. Chapman, W. T. Abraham, S. Zamudio, C. Coffin, A. Merouani, D. Young, A. Johnson, F. Osorio, C. Goldberg, L. G. Moore, T. Dahms, R. W. Schrier, Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 54, 2056-2063 (1998).
3. R. A. Khalil, J. P. Granger, Vascular mechanisms of increased arterial pressure in preeclampsia: Lessons from animal models. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R29-R45 (2002).
4. T. Saito, J. Ishida, E. Takimoto-Ohnishi, S. Takamine, T. Shimizu, T. Sugaya, H. Kato, T. Matsuoka, M. Nangaku, Y. Kon, F. Sugiyama, K. Yagami, A. Fukamizu, An essential role for angiotensin II type 1a receptor in pregnancy-associated hypertension with intrauterine growth retardation. FASEB J. 18, 388-390 (2004).
5. P. N. Baker, F. Broughton Pipkin, E. M. Symonds, Platelet angiotensin II binding and plasma renin concentration, plasma renin substrate and plasma angiotensin II in human pregnancy. Clin. Sci. 79, 403-408 (1990).
6. N. F. Gant, G. L. Daley, S. Chand, P. J. Whalley, P. C. MacDonald, A study of angiotensin II pressor response throughout primigravid pregnancy. J. Clin. Invest. 52, 2682-2689 (1973).
7. R. Serreau, D. Luton, M. A. Macher, A. L. Delezoide, C. Garel, E. Jacqz-Aigrain, Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: A report of 10 cases. BJOG 112,710-712 (2005).
8. W. O. Cooper, S. Hernandez-Diaz, P. G. Arbogast, J. A. Dudley, S. Dyer, P. S. Gideon, K. Hall, W. A. Ray, Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med. 354, 2443-2451 (2006).
9. C. C. Zhou, Y. Zhang, R. A. Irani, H. Zhang, T. Mi, E. J. Popek, M. J. Hicks, S. M. Ramin, R. E. Kellems, Y. Xia, Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat. Med. 14, 855-862 (2008).
10. C. C. Zhou, R. A. Irani, Y. Dai, S. C. Blackwell, M. J. Hicks, S. M. Ramin, R. E. Kellems, Y. Xia, Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J. Immunol. 186, 6024-6034 (2011).
11. 1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med. 7,1003-1009 (2001).
12. L. De Vries, B. Zheng, T. Fischer, E. Elenko, M. G. Farquhar, The regulator of G protein signaling family. Annu. Rev. Pharmacol. Toxicol. 40, 235-271 (2000).
13. M. Manzur, R. Ganss, Regulator of G protein signaling 5: A new player in vascular remodeling. Trends Cardiovasc. Med. 19, 26-30 (2009).
14. V. Holobotovskyy, M. Manzur, M. Tare, J. Burchell, E. Bolitho, H. Viola, L. C. Hool, L. F. Arnolda, D. J. McKitrick, R. Ganss, Regulator of G-protein signaling 5 controls blood pressure homeostasis and vessel wall remodeling. Circ. Res. 112,781-791 (2013).
15. J. Hamzah, M. Jugold, F. Kiessling, P. Rigby, M. Manzur, H. H. Marti, T. Rabie, S. Kaden, H. J. Gröne, G. J. Hämmerling, B. Arnold, R. Ganss, Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453,410-414 (2008).
16. P. Ketsawatsomkron, C. J. Pelham, S. Groh, H. L. Keen, F. M. Faraci, C. D. Sigmund, Does peroxisome proliferator-activated receptor-g (PPARg) protect from hypertension directly through effects in the vasculature? J. Biol. Chem. 285, 9311-9316 (2010).
17. T. Fournier, J. Guibourdenche, K. Handschuh, V. Tsatsaris, B. Rauwel, C. Davrinche, D. Evain-Brion, PPARγ and human trophoblast differentiation. J. Reprod. Immunol. 90,41-49 (2011).
18. M. J. Zarzuelo, R. Jiménez, P. Galindo, M. Sánchez, A. Nieto, M. Romero, A. M. Quintela, R. López-Sepúlveda, M. Gómez-Guzmán, E. Bailón, I. Rodríguez-Gómez, A. Zarzuelo, J. Gálvez, J. Tamargo, F. Pérez-Vizcaíno, J. Duarte, Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats. Hypertension 58, 733-743 (2011).
19. P. Ketsawatsomkron, R. A. Lorca, H. L. Keen, E. T. Weatherford, X. Liu, C. J. Pelham, J. L. Grobe, F. M. Faraci, S. K. England, C. D. Sigmund, PPARg regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ. Res. 111, 1446-1458 (2012).
20. M. A. Hajdu, D. D. Heistad, G. L. Baumbach, Effects of antihypertensive therapy on mechanics of cerebral arterioles in rats. Hypertension 17,308-316 (1991).
21. J. Brewer, R. Liu, Y. Lu, J. Scott, K. Wallace, G. Wallukat, J. Moseley, F. Herse, R. Dechend, J. N. Martin Jr., B. Lamarca, Endothelin-1, oxidative stress, and endogenous angiotensin II: Mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension 62, 886-892 (2013).
22. S. Moncada, D. D. Rees, R. Schulz, R. M. Palmer, Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 88, 2166-2170 (1991).
23. M. Oelze, H. Mollnau, N. Hoffmann, A. Warnholtz, M. Bodenschatz, A. Smolenski, U. Walter, M. Skatchkov, T. Meinertz, T. Munzel, Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ. Res. 87, 999-1005 (2000).
24. J. J. Bonica, Principles and Practice of Obstetric Analgesia & Anesthesia (F. A. Davis Co., Philadelphia, 1967).
25. 13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat. Med. 14, 64-68 (2008).
26. J. S. Gilbert, S. A. Babcock, J. P. Granger, Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50, 1142-1147 (2007).
27. X. Fan, A. Rai, N. Kambham, J. F. Sung, N. Singh, M. Petitt, S. Dhal, R. Agrawal, R. E. Sutton, M. L. Druzin, S. S. Gambhir, B. K. Ambati, J. C. Cross, N. R. Nayak, Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J. Clin. Invest. 124, 4941-4952 (2014).
28. C. C. Zhou, S. Ahmad, T. Mi, L. Xia, S. Abbasi, P. W. Hewett, C. Sun, A. Ahmed, R. E. Kellems, Y. Xia, Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res. 100,88-95 (2007).
29. J. R. Barton, J. M. O'Brien, N. K. Bergauer, D. L. Jacques, B. M. Sibai, Mild gestational hypertension remote from term: Progression and outcome. Am. J. Obstet. Gynecol. 184, 979-983 (2001).
30. C. Marchesi, A. Rehman, Y. Rautureau, D. A. Kasal, M. Briet, A. Leibowitz, S. M. Simeone, T. Ebrahimian, M. F. Neves, S. Offermanns, F. J. Gonzalez, P. Paradis, E. L. Schiffrin, Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease. Cardiovasc. Res. 97, 562-570 (2013).
31. A. R. Saxena, S. A. Karumanchi, N. J. Brown, C. M. Royle, T. F. McElrath, E. W. Seely, Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension 55, 1239-1245 (2010).
32. P. R. Romundstad, E. B. Magnussen, G. D. Smith, L. J. Vatten, Hypertension in pregnancy and later cardiovascular risk: Common antecedents? Circulation 122, 579-584 (2010).
33. M. P. Johnson, S. P. Brennecke, C. E. East, T. D. Dyer, L. T. Roten, J. M. Proffitt, P. E. Melton, M. H. Fenstad, T. Aalto-Viljakainen, K. Makikallio, S. Heinonen, E. Kajantie, J. Kere, H. Laivuori; FINNPEC Study Group, R. Austgulen, J. Blangero, E. K. Moses, Genetic dissection of the pre-eclampsia susceptibility locus on chromosome 2q22 reveals shared novel risk factors for cardiovascular disease. Mol. Hum. Reprod. 19, 423-437 (2013).
34. L. A. Caló, E. Pagnin, P. A. Davis, M. Sartori, G. Ceolotto, A. C. Pessina, A. Semplicini, Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J. Clin. Endocrinol. Metab. 89, 4153-4157 (2004).
35. K. Nadra, L. Quignodon, C. Sardella, E. Joye, A. Mucciolo, R. Chrast, B. Desvergne, PPARγ in placental angiogenesis. Endocrinology 151,4969-4981 (2010).
36. F. P. McCarthy, S. Drewlo, F. A. English, J. Kingdom, E. J. Johns, L. C. Kenny, S. K. Walsh, Evidence implicating peroxisome proliferator-activated receptor-γ in the pathogenesis of preeclampsia. Hypertension 58, 882-887 (2011).
37. N. I. Gokina, S. L. Chan, A. C. Chapman, K. Oppenheimer, T. L. Jetton, M. J. Cipolla, Inhibition of PPARγ during rat pregnancy causes intrauterine growth restriction and attenuation of uterine vasodilation. Front. Physiol. 4, 184 (2013).
38. F. P. McCarthy, S. Drewlo, J. Kingdom, E. J. Johns, S. K. Walsh, L. C. Kenny, Peroxisome proliferator-activated receptor-γ as a potential therapeutic target in the treatment of preeclampsia. Hypertension 58, 280-286 (2011).
39. L. L. Waite, R. E. Louie, R. N. Taylor, Circulating activators of peroxisome proliferator-activated receptors are reduced in preeclamptic pregnancy. J. Clin. Endocrinol. Metab. 90, 620-626 (2005).
40. S. J. Holdsworth-Carson, R. Lim, A. Mitton, C. Whitehead, G. E. Rice, M. Permezel, M. Lappas, Peroxisome proliferator-activated receptors are altered in pathologies of the human placenta: Gestational diabetes mellitus, intrauterine growth restriction and preeclampsia. Placenta 31, 222-229 (2010).
41. P. M. Catalano, H. D. McIntyre, J. K. Cruickshank, D. R. McCance, A. R. Dyer, B. E. Metzger, L. P. Lowe, E. R. Trimble, D. R. Coustan, D. R. Hadden, B. Persson, M. Hod, J. J. Oats; HAPO Study Cooperative Research Group, The hyperglycemia and adverse pregnancy outcome study: Associations of GDM and obesity with pregnancy outcomes. Diabetes Care 35, 780-786 (2012).
42. Y. Jin, X. An, Z. Ye, B. Cully, J. Wu, J. Li, RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells. J. Biol. Chem. 284, 23436-23443 (2009).
43. J. J. Gunaje, A. J. Bahrami, S. M. Schwartz, G. Daum, W. M. Mahoney Jr., PDGF-dependent regulation of regulator of G protein signaling-5 expression and vascular smooth muscle cell functionality. Am. J. Physiol. Cell Physiol. 301, C478-C489 (2011).
44. C. Nunn, M. X. Zou, A. J. Sobiesiak, A. A. Roy, L. A. Kirshenbaum, P. Chidiac, RGS2 inhibits β-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell. Signal. 22, 1231-1239 (2010).
45. L. L. Waite, E. C. Person, Y. Zhou, K. H. Lim, T. S. Scanlan, R. N. Taylor, Placental peroxisome proliferator-activated receptor-g is up-regulated by pregnancy serum. J. Clin. Endocrinol. Metab. 85, 3808-3814 (2000).
46. I. Barroso, M. Gurnell, V. E. Crowley, M. Agostini, J. W. Schwabe, M. A. Soos, G. L. Maslen, T. D. Williams, H. Lewis, A. J. Schafer, V. K. Chatterjee, S. O'Rahilly, Dominant negative mutations in human PPARg associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883 (1999).
47. Y. P. Chang, X. Liu, J. D. Kim, M. A. Ikeda, M. R. Layton, A. B. Weder, R. S. Cooper, S. L. Kardia, D. C. Rao, S. C. Hunt, A. Luke, E. Boerwinkle, A. Chakravarti, Multiple genes for essentialhypertension susceptibility on chromosome 1q. Am. J. Hum. Genet. 80, 253-264 (2007).
48. B. Xiao, Y. Zhang, W. Q. Niu, P. J. Gao, D. L. Zhu, Haplotype-based association of regulator of G-protein signaling 5 gene polymorphisms with essential hypertension and metabolic parameters in Chinese. Clin. Chem. Lab. Med. 47, 1483-1488 (2009).
49. M. U. Faruque, G. Chen, A. Doumatey, H. Huang, J. Zhou, G. M. Dunston, C. N. Rotimi, A. A. Adeyemo, Association of ATP1B1, RGS5 and SELE polymorphisms with hypertension and blood pressure in African-Americans. J. Hypertens. 29,1906-1912 (2011).
50. P. Froment, P. Touraine, Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR Res. 2006, 1-8 (2006).
51. J. Kung, R. R. Henry, Thiazolidinedione safety. Expert Opin. Drug Saf. 11, 565-579 (2012).
52. T. Chaiworapongsa, P. Chaemsaithong, L. Yeo, R. Romero, Pre-eclampsia part 1: Current understanding of its pathophysiology. Nat. Rev. Nephrol. 10, 466-480 (2014).
53. F. P. McCarthy, J. C. Kingdom, L. C. Kenny, S. K. Walsh, Animal models of preeclampsia; Uses and limitations. Placenta 32, 413-419 (2011).
54. J. Hamzah, D. Nelson, G. Moldenhauer, B. Arnold, G. J. Hammerling, R. Ganss, Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118, 1691-1699 (2008).
55. R. Holtwick, M. Gotthardt, B. Skryabin, M. Steinmetz, R. Potthast, B. Zetsche, R. E. Hammer, J. Herz, M. Kuhn, Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc. Natl. Acad. Sci. U.S.A. 99, 7142-7147 (2002).
56. M. Oppermann, B. Gess, F. Schweda, H. Castrop, Atrap deficiency increases arterial blood pressure and plasma volume. J. Am. Soc. Nephrol. 21, 468-477 (2010).